| Human immunodeficiency virus I infection

Apretude vs Triumeq

Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.

Deep comparison between: Apretude vs Triumeq with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTriumeq has a higher rate of injection site reactions vs Apretude based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Triumeq but not Apretude, including UnitedHealthcare

Category

Apretude

Triumeq

At A Glance

RouteIM injection

FrequencyEvery 2 months

ClassHIV integrase strand transfer inhibitor

RouteOral

FrequencyOnce daily

ClassINSTI + dual NRTI antiretroviral combination

Indications

Human immunodeficiency virus I infection

Human immunodeficiency virus I infection

Dosing

Human immunodeficiency virus I infection 600-mg (3-mL) gluteal IM initiation injections 1 month apart for 2 consecutive months, then 600-mg (3-mL) every 2 months; optional oral lead-in with cabotegravir 30 mg once daily for at least 28 days prior to first injection.

Human immunodeficiency virus I infection Adults: One tablet of TRIUMEQ (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) once daily orally with or without food. Pediatric patients >=25 kg: One tablet TRIUMEQ once daily. Pediatric patients 6 to <10 kg: 3 tablets TRIUMEQ PD (180 mg abacavir, 15 mg dolutegravir, 90 mg lamivudine) once daily dispersed in water. Pediatric patients 10 to <14 kg: 4 tablets TRIUMEQ PD (240 mg abacavir, 20 mg dolutegravir, 120 mg lamivudine) once daily dispersed in water. Pediatric patients 14 to <20 kg: 5 tablets TRIUMEQ PD (300 mg abacavir, 25 mg dolutegravir, 150 mg lamivudine) once daily dispersed in water. Pediatric patients 20 to <25 kg: 6 tablets TRIUMEQ PD (360 mg abacavir, 30 mg dolutegravir, 180 mg lamivudine) once daily dispersed in water. Screen for HLA-B*5701 allele and test for HBV infection before initiating. Adjust dolutegravir to 50 mg twice daily when coadministered with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampin.

Contraindications

Unknown or positive HIV-1 status
Previous hypersensitivity reaction to cabotegravir
Coadministration with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin) due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
Coadministration with antimycobacterials rifampin or rifapentine due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations

Presence of HLA-B*5701 allele
Prior hypersensitivity reaction to abacavir, dolutegravir, or lamivudine
Concomitant use with dofetilide
Moderate or severe hepatic impairment

Drug Interactions

1117View drug interactions

3171View drug interactions

Adverse Reactions

Most common (>=1%) Injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, upper respiratory tract infection

Serious Hypersensitivity reactions, hepatotoxicity, depressive disorders including depression, suicidal ideation, and suicide attempt

Postmarketing Hypersensitivity reactions (angioedema, urticaria), Stevens-Johnson syndrome/toxic epidermal necrolysis

Most common (>=2%) Insomnia, headache, fatigue, nausea, diarrhea

Serious Serious and sometimes fatal hypersensitivity reaction with abacavir, exacerbations of hepatitis B, hepatotoxicity, lactic acidosis and severe hepatomegaly with steatosis, immune reconstitution syndrome, myocardial infarction

Postmarketing Aplastic anemia, anemia, lymphadenopathy, splenomegaly, stomatitis, pancreatitis, acute liver failure, sensitization reactions including anaphylaxis and urticaria, weight increase, hyperlactemia, CPK elevation, muscle weakness, myalgia, rhabdomyolysis, peripheral neuropathy, seizures, anxiety, alopecia, erythema multiforme, suspected Stevens-Johnson syndrome, toxic epidermal necrolysis

Pharmacology

Cabotegravir is an HIV integrase strand transfer inhibitor (INSTI) that inhibits HIV replication by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for the HIV replication cycle.

TRIUMEQ and TRIUMEQ PD are fixed-dose combinations of three HIV-1 antiretroviral agents: dolutegravir (an integrase strand transfer inhibitor that blocks HIV replication by binding to the integrase active site and inhibiting the strand transfer step), abacavir (a nucleoside analogue that is converted to carbovir triphosphate which inhibits HIV-1 reverse transcriptase by competing with dGTP and incorporating into viral DNA), and lamivudine (a nucleoside analogue phosphorylated to lamivudine triphosphate which inhibits reverse transcriptase via DNA chain termination).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Apretude